Back to Journals » Drug Design, Development and Therapy » Volume 9

Pirfenidone-loaded liposomes for lung targeting: preparation and in vitro/in vivo evaluation

Authors Meng H, Xu Y

Received 5 March 2015

Accepted for publication 16 April 2015

Published 30 June 2015 Volume 2015:9 Pages 3369—3376

DOI https://doi.org/10.2147/DDDT.S84046

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Wei Duan


Hui Meng, Yong Xu

Department of Pharmaceuticals, 85th People’s Liberation Army Hospital, Shanghai, People’s Republic of China

Background: The purpose of this study was to develop novel pirfenidone (PFD)-loaded liposomes for targeting to the lung.
Methods: The liposomes were prepared by the film hydration method, and their in vitro/vivo characteristics were evaluated.
Results: The PFD liposomes appeared visually as green to yellowish suspensions and were spherical in shape. The particle size was 582.3±21.6 nm and the entrapment efficiency was relatively high (87.2%±5.7%). The liposomes showed typical sustained and prolonged drug-release behavior in vitro and fitted well with the Weibull distribution equation. The relatively slower time taken to reach a minimal plasma PFD concentration in vivo suggests that PFD liposomes have a sustained-release profile, which is consistent with the results of the in vitro release study. The PFD liposomes showed the largest area under the curve for the lung. The high distribution of PFD achieved in the lungs using this liposomal formulation may be explained by physical entrapment of the liposomes in the vascular network of the lung. Histopathological results indicated that liposomal PFD could alleviate pathological injury in lung tissue.
Conclusion: This liposomal formulation can enable sustained release of PFD and increase targeting to the lung.

Keywords: pirfenidone, liposomes, lung targeting, in vivo, histopathological
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]